Merck And Ridgeback Biotherapeutics Provide Update On Results From MOVe-OUT Study Of Molnupiravir; Molnupiravir Reduced Risk Of Hospitalization Or Death From 9.7% In Placebo Group To 6.8% In Molnupiravir Group